These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 32135540)

  • 1. Human Telomerase Reverse Transcriptase Gene Promoter Mutation in Serum of Patients with Hepatocellular Carcinoma.
    Ako S; Nouso K; Kinugasa H; Matsushita H; Terasawa H; Adachi T; Wada N; Takeuchi Y; Mandai M; Onishi H; Ikeda F; Shiraha H; Takaki A; Fujioka S; Mimura T; Okada H
    Oncology; 2020; 98(5):311-317. PubMed ID: 32135540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of the prognosis of advanced hepatocellular carcinoma by TERT promoter mutations in circulating tumor DNA.
    Hirai M; Kinugasa H; Nouso K; Yamamoto S; Terasawa H; Onishi Y; Oyama A; Adachi T; Wada N; Sakata M; Yasunaka T; Onishi H; Shiraha H; Takaki A; Okada H
    J Gastroenterol Hepatol; 2021 Apr; 36(4):1118-1125. PubMed ID: 32830343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.
    Akuta N; Kawamura Y; Kobayashi M; Arase Y; Saitoh S; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Suzuki F; Ikeda K; Kumada H
    Oncology; 2021; 99(2):114-123. PubMed ID: 32998139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma.
    Yang X; Guo X; Chen Y; Chen G; Ma Y; Huang K; Zhang Y; Zhao Q; Winkler CA; An P; Lyu J
    Oncotarget; 2016 May; 7(19):27838-47. PubMed ID: 27056898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.
    Muraoka M; Maekawa S; Katoh R; Komiyama Y; Nakakuki N; Takada H; Matsuda S; Suzuki Y; Sato M; Tatsumi A; Miura M; Amemiya F; Shindo H; Takano S; Fukasawa M; Yamauchi K; Yamaguchi T; Nakayama Y; Inoue T; Enomoto N
    Hepatol Commun; 2021 Nov; 5(11):1927-1938. PubMed ID: 34558819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of combined circulating TERT promoter mutations and miR-122 expression for screening HBV-related hepatocellular carcinoma.
    Trung NT; Hoan NX; Trung PQ; Binh MT; Van Tong H; Toan NL; Bang MH; Song LH
    Sci Rep; 2020 May; 10(1):8181. PubMed ID: 32424223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of TERT promoter mutation in serum cell-free DNA using wild-type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma.
    Akuta N; Suzuki F; Kobayashi M; Fujiyama S; Kawamura Y; Sezaki H; Hosaka T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Suzuki Y; Kumada H
    J Med Virol; 2020 Dec; 92(12):3604-3608. PubMed ID: 32100879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological characteristics of TERT promoter mutation and telomere length in hepatocellular carcinoma.
    Lee HW; Park TI; Jang SY; Park SY; Park WJ; Jung SJ; Lee JH
    Medicine (Baltimore); 2017 Feb; 96(5):e5766. PubMed ID: 28151853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum human telomerase reverse transcriptase messenger RNA as a novel tumor marker for hepatocellular carcinoma.
    Miura N; Maeda Y; Kanbe T; Yazama H; Takeda Y; Sato R; Tsukamoto T; Sato E; Marumoto A; Harada T; Sano A; Kishimoto Y; Hirooka Y; Murawaki Y; Hasegawa J; Shiota G
    Clin Cancer Res; 2005 May; 11(9):3205-9. PubMed ID: 15867214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative peripheral blood human telomerase reverse transcriptase mRNA concentration is not a prognostic factor for resection of hepatocellular carcinoma.
    Kim YD; Hwang S; Lee YJ; Kim KH; Ahn CS; Park KM; Moon DB; Ha TY; Song GW; Jung DH; Park SR; Hong HN; Lee SG
    Hepatogastroenterology; 2012; 59(117):1512-5. PubMed ID: 22683968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha-fetoprotein and human telomerase reverse transcriptase mRNA levels in peripheral blood of patients with hepatocellular carcinoma.
    Kong SY; Park JW; Kim JO; Lee NO; Lee JA; Park KW; Hong EK; Kim CM
    J Cancer Res Clin Oncol; 2009 Aug; 135(8):1091-8. PubMed ID: 19184104
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human telomerase reverse transcriptase messenger RNA (TERT mRNA) as a tumour marker for early detection of hepatocellular carcinoma.
    El-Mazny A; Sayed M; Sharaf S
    Arab J Gastroenterol; 2014 Jun; 15(2):68-71. PubMed ID: 25097049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutated circulating tumor DNA as a biomarker for prognosis in hepatocellular carcinoma.
    Oversoe SK; Clement MS; Pedersen MH; Weber B; Aagaard NK; Villadsen GE; Grønbæk H; Hamilton-Dutoit SJ; Sorensen BS; Kelsen J
    Scand J Gastroenterol; 2020 Dec; 55(12):1433-1440. PubMed ID: 33103505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TERT promoter SNP rs2853669 decreases E2F1 transcription factor binding and increases mortality and recurrence risks in liver cancer.
    Ko E; Seo HW; Jung ES; Kim BH; Jung G
    Oncotarget; 2016 Jan; 7(1):684-99. PubMed ID: 26575952
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TERT promoter mutation incidence is modified by germline TERT rs2736098 and rs2736100 polymorphisms in hepatocellular carcinoma.
    Yuan X; Cheng G; Yu J; Zheng S; Sun C; Sun Q; Li K; Lin Z; Liu T; Li P; Xu Y; Kong F; Bjorkholm M; Xu D
    Oncotarget; 2017 Apr; 8(14):23120-23129. PubMed ID: 28416747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments.
    Campani C; Imbeaud S; Couchy G; Ziol M; Hirsch TZ; Rebouissou S; Noblet B; Nahon P; Hormigos K; Sidali S; Seror O; Taly V; Ganne Carrie N; Laurent-Puig P; Zucman-Rossi J; Nault JC
    Gut; 2024 Oct; 73(11):1870-1882. PubMed ID: 39054058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
    Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
    Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of genes involved in the regulation of TERT in hepatocellular carcinoma.
    Amisaki M; Tsuchiya H; Sakabe T; Fujiwara Y; Shiota G
    Cancer Sci; 2019 Feb; 110(2):550-560. PubMed ID: 30447097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.